Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma is the indication for 4 drugs in DrugBank. It is covered by 4 curated, structured indications.

Also known as: Hodgkin's disease refractory · refractory Hodgkin's disease · refractory Hodgkin's lymphoma · Hodgkin Disease Refractory · refractory Hodgkin Disease
Classified under: Hemic and Lymphatic Diseases
Immune System Diseases
Neoplasms
Indicated drugs: Bendamustine
Carboplatin
Carmustine
Lomustine

Resolves to

Vocabularies

SNOMED CT461311000124107MedDRA10020257UMLSC0855082

What you can answer from here — as of November 13, 2026

4Indicated drugsWith each drug's targets and mechanism

Listed above

4Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

72Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Refractory Hodgkin Lymphoma share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.